What Is New With Rosacea and Acne in September 2026? Latest FDA and dermatology sources and Key Takeaways

As of September 8, 2026, the FDA has announced no new acne or rosacea drug approval for September. The meaningful updates are expanded nonprescription access to an acne treatment, delayed isotretinoin-program changes, and current dermatology guidance on effective care. The FDA's 2026 novel-drug roster lists only an Alexander disease treatment for September, not an acne or rosacea therapy. Any claim about a new September FDA drug for these skin conditions is therefore unsupported by the FDA's current approval roster.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Official resources:

Read the official notice from FDA — Use this primary source to verify the official announcement.
Read the official notice from FDA — Use this primary source to verify the official announcement.

What changed for over-the-counter acne treatment?
What is happening with isotretinoin and iPLEDGE?
Should benzoyl peroxide users worry about benzene?
What are the practical rosacea updates?
How should readers act on the evidence?

What changed for over-the-counter acne treatment?

On May 22, 2026, the FDA approved Differin Epiduo acne Gel for a prescription-to-nonprescription switch. It combines adapalene 0.1%, a topical retinoid, with benzoyl peroxide 2.5%. The switch expands potential over-the-counter access for adults and children aged 12 and older, according to the FDA's prescription-to-nonprescription switch list.

It is a significant access change, but it is not a September novel-drug approval. People comparing acne products should check both active ingredients, not just the brand name. A combination gel differs from a product containing only adapalene or only benzoyl peroxide.

What is happening with isotretinoin and iPLEDGE?

Isotretinoin is used for acne under iPLEDGE, a safety program designed to prevent fetal exposure because the drug can cause severe birth defects. Planned 2026 program changes will not begin as early as previously expected. The FDA postponed implementation from august 8 to November 15, 2026, while the updated system undergoes testing.

Until then, patients, prescribers, and pharmacies remain subject to the existing requirements described on the FDA's iPLEDGE information page. Once implemented, the changes may allow prescriber-authorized home pregnancy tests during and after treatment. Pretreatment pregnancy testing must still take place in a medical setting. Patients should follow their prescriber's current instructions rather than assuming the future rules already apply.

Should benzoyl peroxide users worry about benzene?

FDA testing provides useful context for earlier concerns about benzene in benzoyl-peroxide acne products. Of 95 products tested, more than 90% contained undetectable or extremely low benzene levels. A limited group of products underwent voluntary retail-level recalls.

The FDA said the cancer risk from the detected contamination was very low, even with daily use for decades. That finding does not mean every past product was unaffected. Consumers who still have an older benzoyl-peroxide product can check its identity and expiration information against FDA recall details or ask a pharmacist whether it was involved.

What are the practical rosacea updates?

Emrosi, extended-release minocycline 40 mg, remains an FDA-approved once-daily treatment for inflammatory rosacea papules and pustules in adults. These are the acne-like bumps associated with rosacea. Emrosi has not been evaluated for treating or preventing infections. It also carries tetracycline-class safety warnings, so it should not be treated as a general-purpose antibiotic or used without considering its prescribing information.

Rosacea can resemble acne, sunburn, or another skin reaction. Persistent facial color, flushing, sensitive skin, eye irritation, or acne-like breakouts warrant a dermatologic assessment because the correct diagnosis changes treatment. Rosacea therapy also requires patience. The American Academy of Dermatology says topical treatment may produce slight improvement within three to four weeks, while noticeable change often takes two to three months, as explained in its diagnosis and treatment guidance.

How should readers act on the evidence?

The current American Academy of Dermatology acne guideline supports benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. It favors combining topical treatments and limiting systemic antibiotics to reduce resistance and complications.

A practical next step depends on the situation: Do not assume that acne-like bumps are ordinary acne. Rosacea treatment can take months to show a noticeable result, and choosing the wrong condition's treatment may delay appropriate care.

For mild acne, compare active ingredients and confirm that the product fits the user's age.
For isotretinoin, follow the current iPLEDGE process until the November 15 changes take effect.
For persistent redness, flushing, eye irritation, or acne-like bumps, seek an assessment for possible rosacea.
For a new topical rosacea treatment, allow the recommended trial period unless irritation or another concerning reaction requires earlier medical advice.
For oral antibiotics, ask how long treatment is expected to continue and what non-antibiotic treatments form the longer-term plan.